

## ASX ANNOUNCEMENT

### Appendix 4C – Quarterly Cash Flow Report

#### Highlights for the quarter ended 31st March 2019

- **Chairman, Dr Monsour presents PeriCoach real world data analysis at Urological Society of Australia and New Zealand, demonstrating outstanding improvement for women.**
- **PeriCoach CE-Marked for Pelvic Organ Prolapse**
- **\$745k research & development tax incentive received**
- **Cash balance at 31<sup>st</sup> March \$1,598k.**

**30th April 2019:** Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system and the AutoStart® and AutoFlush infusion system technologies, has today released its Appendix 4C - Quarterly Cashflow report for the period ending 31<sup>st</sup> March 2019.

On 15<sup>th</sup> April, Analytica Chairman Dr Monsour presented the latest PeriCoach real-world evidence at the 2019 Urological Society of Australia and New Zealand (USANZ) annual meeting. The poster presentation "PeriCoach Structured Programming and Effect of Clinical Engagement" outlined the outcome analysis for improvement in strength and reported reduction in urine volume and leakage episodes of users of the PeriCoach V3 completing the PeriCoach 8 Week Challenge program. Specifically, bladder leakage episode and volume improvements for all users reached statistically significant levels by week 3 and beyond, and strength reached significance by week 5 and beyond. By week 8, 75% of users demonstrated 80% or more reduction in urine volume and episodes.

The PeriCoach system is now CE-Marked to assist in the conservative treatment of Pelvic Organ Prolapse (POP) in addition to urinary incontinence (UI). This expansion of clinical indications allows PeriCoach to be marketed in Europe for the conservative treatment of POP. PeriCoach remains the only smartphone pelvic floor muscle rehabilitation system indicated for women to target resolution of symptoms for mild to moderate POP, UI and sexual wellness. This follows the company's Australian clearance for POP announced 2 May 2018. Analytica is investigating regulatory pathways for clearance in the US for treatment of POP.

Pelvic organ prolapse is a very common condition with 40% of women over 50 years having some degree of prolapse when examined<sup>1</sup>. The symptoms of POP (feeling of heaviness, back pain, constipation, incontinence) have a significant impact on quality of life. It is estimated that by the age of 80 almost one in eight (12.2%) will have had a surgical intervention<sup>2</sup>.

For several years there have been concerns globally about urogynaecological surgical mesh implants for POP. Recent regulatory responses include the Australian TGA up-classification of all surgical meshes to Class III, and the US FDA's recent order in April 2019 for mesh manufacturers to stop sales of meshes for cystocele prolapse. Professional guidelines<sup>3</sup> recommend non-surgical interventions including proper and consistent pelvic floor muscle exercises as the first line of treatment for SUI. The increasing regulatory

<sup>1</sup> Lancet 2014; 383: 796–806 [http://dx.doi.org/10.1016/S0140-6736\(13\)61977-7](http://dx.doi.org/10.1016/S0140-6736(13)61977-7)

<sup>2</sup> Abdel-fattah M, Familusi A, Fielding S, et al. Primary and repeat surgical treatment for female pelvic organ prolapse and incontinence in parous women in the UK: a register linkage study. BMJ Open 2011;1:e000206. doi:10.1136/bmjopen-2011-000206

<sup>3</sup> [https://www.auanet.org/guidelines/stress-urinary-incontinence-\(sui\)-guideline](https://www.auanet.org/guidelines/stress-urinary-incontinence-(sui)-guideline)



constraints on surgery will pressure clinicians treating pelvic floor disorders around the world towards conservative treatments including pelvic floor muscle exercise. PeriCoach has the capability to provide clinicians with evidence of compliance and efficacy for pelvic floor exercise.

Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$13k. The marketing activity, \$57k, is focused on recruitment for data collection and feature development. Research & development expenditure was \$199k, dominated by investment on the PeriCoach "big data" project, the largest and most comprehensive pelvic floor muscle exercise data repository and analysis platform in the world. Staff costs of \$257k was incurred and administration costs \$121k.

The company has access to a \$400k loan facility. Directors are monitoring capital requirements to ensure the company has adequate cash to continue development and undertake partnering negotiations of the PeriCoach and the AutoFlush and AutoStart burette technologies. The Company continues to have the financial support of its major shareholders.

As outlined in the Chairman's address to the Annual General Meeting in November 2017, Analytica is achieving its goals set out at the Annual General meeting 2016 of being deal-ready. This quarter demonstrates further strong progress to the Company strategy; build a product that is best in class, gather evidence that the product performance is exceptional, and actively pursue partnering opportunities.

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

### About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, CE mark and USFDA 510(k) clearance. The product is available for sale from [pericoach.com](http://pericoach.com) in Australia and New Zealand, UK and Ireland, and the US.



## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Analytica Ltd

**ABN**

12 006 464 866

**Quarter ended ("current quarter")**

March 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	13	39
1.2 Payments for		
(a) research and development	(199)	(692)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(57)	(165)
(d) leased assets		
(e) staff costs	(257)	(787)
(f) administration and corporate costs	(121)	(387)
1.3 Dividends received (see note 3)		
1.4 Interest received	3	15
1.5 Interest and other costs of finance paid	-	(2)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	745	745
1.8 Other (provide details if material)	5	5
<b>1.9 Net cash from / (used in) operating activities</b>	<b>132</b>	<b>(1,229)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment		(1)
(b) businesses (see item 10)		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	<b>Net cash from / (used in) investing activities</b>		<b>(1)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of shares		
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options		(13)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	<b>Net cash from / (used in) financing activities</b>		<b>(13)</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,466	2,841
4.2	Net cash from / (used in) operating activities (item 1.9 above)	132	(1,229)
4.3	Net cash from / (used in) investing activities (item 2.6 above)		(1)
4.4	Net cash from / (used in) financing activities (item 3.10 above)		(13)

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held		
4.6	<b>Cash and cash equivalents at end of quarter</b>	<b>1,598</b>	<b>1,598</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	1,598	1,598
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>1,598</b>	<b>1,598</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter \$A'000</b>
96
0

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

<b>Current quarter \$A'000</b>

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	400	0
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	190
9.2 Product manufacturing and operating costs	50
9.3 Advertising and marketing	50
9.4 Leased assets	
9.5 Staff costs	260
9.6 Administration and corporate costs	90
9.7 Other (provide details if material)	
<b>9.8 Total estimated cash outflows</b>	<b>640</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

### **Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: ..... Date: ....30<sup>th</sup> April 2019.  
(Director)

Print name: R. Mangelsdorf

### **Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.